.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Cipla
UBS
Daiichi Sankyo
Teva
QuintilesIMS
Medtronic
Accenture
Queensland Health
Citi

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,879,842

« Back to Dashboard

Which drugs does patent 7,879,842 protect, and when does it expire?


Patent 7,879,842 protects CORLANOR and is included in one NDA.

This patent has forty-six patent family members in forty-one countries.

Summary for Patent: 7,879,842

Title:Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Abstract: .beta.-Crystalline form of ivabradine of formula (I): ##STR00001## characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as bradycardics.
Inventor(s): Horvath; Stephane (La Chapelle-Saint-Mesmin, FR), Auguste; Marie-Noelle (Orleans, FR), Damien; Gerard (Meung-sur-Loire, FR)
Assignee: Les Laboratoires Servier (Suresnes Cedex, FR)
Application Number:12/589,283
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Amgen IncCORLANORivabradine hydrochlorideTABLET;ORAL206143-001Apr 15, 2015RXYesNo► Subscribe► SubscribeYYA METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE► Subscribe
Amgen IncCORLANORivabradine hydrochlorideTABLET;ORAL206143-002Apr 15, 2015RXYesYes► Subscribe► SubscribeYYA METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,879,842

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France05 01985Feb 28, 2005

Non-Orange Book Patents for Patent: 7,879,842

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,361,649.beta.-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,879,842

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea100827502► Subscribe
South Korea20060095501► Subscribe
Japan4625776► Subscribe
Japan2006241154► Subscribe
Israel173957► Subscribe
Jordan2548► Subscribe
CroatiaP20080520► Subscribe
Hong Kong1096387► Subscribe
Guatemala200600084► Subscribe
Georgia, Republic ofP20084465► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Colorcon
US Department of Justice
McKesson
Cerilliant
US Army
Accenture
Johnson and Johnson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot